Brokerages expect Audentes Therapeutics Inc (NASDAQ:BOLD) to report ($0.88) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have provided estimates for Audentes Therapeutics’ earnings. The lowest EPS estimate is ($0.93) and the highest is ($0.79). Audentes Therapeutics also posted earnings of ($0.88) per share during the same quarter last year. The business is expected to issue its next earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Audentes Therapeutics will report full-year earnings of ($3.31) per share for the current fiscal year, with EPS estimates ranging from ($3.50) to ($2.82). For the next fiscal year, analysts expect that the firm will post earnings of ($3.71) per share, with EPS estimates ranging from ($4.59) to ($3.01). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Audentes Therapeutics.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.07).

BOLD has been the subject of a number of recent research reports. Chardan Capital initiated coverage on shares of Audentes Therapeutics in a report on Monday, June 25th. They issued a “neutral” rating and a $35.00 price objective for the company. BidaskClub cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 28th. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a report on Tuesday, July 10th. William Blair reiterated a “buy” rating on shares of Audentes Therapeutics in a report on Tuesday, August 7th. Finally, Mizuho upgraded shares of Audentes Therapeutics from a “neutral” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Wednesday, August 8th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the stock. Audentes Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $35.90.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 21,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $38.16, for a total transaction of $801,360.00. Following the completion of the sale, the chief executive officer now directly owns 17,144 shares in the company, valued at $654,215.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Suyash Prasad sold 10,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $36.88, for a total transaction of $368,800.00. Following the sale, the vice president now owns 100 shares of the company’s stock, valued at $3,688. The disclosure for this sale can be found here. Insiders sold 77,039 shares of company stock valued at $2,925,260 over the last quarter. 6.60% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Partner Investment Management L.P. bought a new stake in Audentes Therapeutics during the second quarter valued at about $162,000. Dynamic Technology Lab Private Ltd bought a new stake in Audentes Therapeutics during the second quarter valued at about $226,000. Quantitative Systematic Strategies LLC bought a new stake in Audentes Therapeutics during the second quarter valued at about $231,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Audentes Therapeutics during the second quarter valued at about $232,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Audentes Therapeutics during the first quarter valued at about $204,000. Institutional investors own 96.74% of the company’s stock.

NASDAQ:BOLD traded down $0.78 during trading hours on Friday, reaching $27.49. The company’s stock had a trading volume of 6,196 shares, compared to its average volume of 429,142. The stock has a market capitalization of $1.48 billion, a PE ratio of -8.16 and a beta of 0.73. Audentes Therapeutics has a one year low of $24.51 and a one year high of $46.18.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.